drugset / Trial / NCT07296146

Probiotics Against Erythropoietin Resistance in Chronic Kidney Disease Patients.

NCT07296146

Phase 3 Not yet recruiting 80 enrolled Badr University
RandomizedParallel-groupSingle-blindTreatment

Summary

The goal of this clinical trial is to assess whether probiotic supplementation can improve the hematological response of CKD patients to erythropoietin therapy and prevent or reduce erythropoietin resistance. The main questions it aims to answer are: Can probiotic be used as an adjuvant strategy in anemia management and increasing ESA responsiveness in CKD? What medical problems do participants have when taking probiotic? Researchers will compare Erythropoietin only with Erythropoietin + Probiotic to see if Probiotic aids in treating anaemic chronic kidney disease patients. Participants will: Take Erythropoietin + Probiotic or Probiotic only every day for 3 months Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms

Timeline

Start
2025-12-15
Primary completion
2026-03-15
Completion
2026-05-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lactobacillus acidophilus Other / unclassified 5 unknown
Comparator epoetin alfa Protein / enzyme biologic 4000 iu